Results 141 to 150 of about 8,661 (182)

Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial. [PDF]

Trials
Blomberg B, Myklebust NN, Oppegaard O, Tøndel C, Cox RJ, Iversen A, Lehmann ME, Sandvig A, Dahl TB, Valderhaug VD, Szodoray P, Wilhelmsen M, Kirsebom BE, Glambek M, Kaarbøe O, Aukrust P, Lie RT, Langeland N.   +17 more
europepmc   +1 more source

An intrinsic loop-mediated structural stability modulating inhibitor potency in the SADS-CoV and SARS-CoV-2 main proteases. [PDF]

PLoS Pathog
Zeng R, Cui S, Xia X, Huang C, Sun J, Deng X, Gui Q, Fan H, Liu X, Yu Y, Yang S, Lei J.   +11 more
europepmc   +1 more source

Rapid establishment of public sector COVID-19 test-and-treatment programmes across seven low- and middle-income countries: implementation strategies and program monitoring results. [PDF]

BMJ Glob Health
Boeke CE, Hamza N, Agwuocha C, Amako O, Detleuxay K, Gao M, Griffith BC, Gumulira Y, Urli Hodges E, Joseph J, Lufesi N, Macharia E, Mbewe N, McCarthy E, Mintah FO, Mukiibi M, Mulenga M, Ngwije A, Ofori-Boadu L, Okoli IU, Phongphila S, Ramers C, Regan S, Twinomujuni E, Rwagasore E, Tebor J, Udayakumar K, COVID-19 Treatment QuickStart Consortium.   +27 more
europepmc   +1 more source

Combination Treatment of Persistent SARS-CoV-2 Infection with Dual Antiviral Therapy and Intravenous Immunoglobulin: A Novel Approach. [PDF]

J Clin Med
Blizou M, Lampadakis S, Karofylakis E, Blizou A, Thomas K, Prountzos S, Papavasileiou V, Raptakis T, Manali ED, Papiris SA, Loukides S, Antonogiannaki EM.   +11 more
europepmc   +1 more source

Persistent COVID-19 Pneumonia in a Patient on Rituximab. [PDF]

J Investig Med High Impact Case Rep
Clarke K, Naidu S, Wan C, Stampfer S.
europepmc   +1 more source

Pharmacist follow-up of patients prescribed nirmatrelvir/ritonavir: a single-center retrospective analysis. [PDF]

J Pharm Health Care Sci
Shigeno A, Ohashi Y, Masui R, Kiryu A, Nagashima K, Ohashi H, Seto K, Masuda J, Teruya K, Ujiie M, Ohmagari N, Nishimura T.   +11 more
europepmc   +1 more source

Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study. [PDF]

Open Forum Infect Dis
Dalton AF, Baca S, Raykin J, Gregory CO, Boehmer T, Koumans EH, Patel PR, Patel P, Saydah S.   +8 more
europepmc   +1 more source

Omicron Subvariants Infection Kinetics and Nirmatrelvir Efficacy in Transgenic K18-hACE2 Mice. [PDF]

Int J Mol Sci
Sharma V, Dolgov E, Tillery T, Mendez Romero C, Rojas-Triana A, Villalba Guzman DM, Goldgirsh K, Rasheed R, Gonzalez-Jimenez I, Alvarez N, Park S, Murugan M, Nelson AM, Perlin DS.   +13 more
europepmc   +1 more source

Real-World Effectiveness of Nirmatrelvir-Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study. [PDF]

Open Forum Infect Dis
Kuo RN, Chen W, Shau WY, Chang SC.
europepmc   +1 more source